SCHEMBL8070862

SCHEMBL8070862

CCCCCc1cccc2c1Cc1ccccc1CN2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
LIPG Q9Y5X9 1/20 0.39
DRD2 P14416 4/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 2/20 0.39
HTR2A P28223 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
CHRM2 P08172 1/20 0.39
CYP3A4 P08684 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
CYP2C9 P11712 1/20 0.39
ADRA2B P18089 1/20 0.39
DRD1 P21728 1/20 0.39
DRD4 P21917 1/20 0.39
DRD5 P21918 1/20 0.39
MAPK1 P28482 1/20 0.39
ADRA1A P35348 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28856434 0.78 NR1H2 (0.39) ALOX15HSD17B10LIPGCYP2D6CYP2C19
SCHEMBL5823386 0.75 PNMT (0.58) LIPGDRD2CYP2D6CYP2C19DRD4
SCHEMBL28825898 0.74 PNMT (0.57) LIPGDRD2CYP2D6CYP2C19HTR2A
SCHEMBL29911116 0.74 PNMT (0.57) LIPGDRD2CYP2D6CYP2C19HTR2A
SCHEMBL6675428 0.74 PNMT (0.57) LIPGDRD2CYP2D6CYP2C19HTR2A
SCHEMBL574897 0.74 LIPG (0.42) LIPGHTR2AHTR2BKCNH2ALOX5
SCHEMBL407782 0.74 PNMT (0.57) LIPGDRD2CYP2D6CYP2C19HTR2A
SCHEMBL6672769 0.74 PNMT (0.57) LIPGDRD2CYP2D6CYP2C19HTR2A
SCHEMBL1449245 0.74 PNMT (0.57) LIPGDRD2CYP2D6CYP2C19HTR2A
SCHEMBL28103115 0.74 PNMT (0.57) LIPGDRD2CYP2D6CYP2C19HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032394-A1 USE OF SUBSTITUTED 11-PHENYL-DIBENZAZEPINE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION, DIARRHEA AND SCOUR CHILDREN'S MEDICAL CENTER CORPORATION (US) 2000-09-06 EP disclosed
WO-1999026628-A1 USE OF SUBSTITUTED 11-PHENYL-DIBENZAZEPINE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION, DIARRHEA AND SCOUR CHILDREN'S MEDICAL CENTER CORPORATION (US) 1999-06-03 WO disclosed